Share the Tech
Prepare for the Future
Currently, many low- and middle-income countries (LMICs) are almost entirely dependent on imports and donations of COVID and other vaccines, contributing to vaccine inequity.
If Moderna, Pfizer and BioNTech shared their mRNA vaccine technology and know-how with the rest of the world, the production and supply of lifesaving vaccines could be diversified and expanded, for COVID and beyond.
With access to mRNA technology, capable manufacturers in LMICs could produce vaccines for emerging COVID variants, as well as other infectious diseases such as HIV, tuberculosis and malaria. They could also be prepared to swiftly produce vaccines for future pandemics.
Prepare for the Future
Currently, many low- and middle-income countries (LMICs) are almost entirely dependent on imports and donations of COVID and other vaccines, contributing to vaccine inequity.
If Moderna, Pfizer and BioNTech shared their mRNA vaccine technology and know-how with the rest of the world, the production and supply of lifesaving vaccines could be diversified and expanded, for COVID and beyond.
With access to mRNA technology, capable manufacturers in LMICs could produce vaccines for emerging COVID variants, as well as other infectious diseases such as HIV, tuberculosis and malaria. They could also be prepared to swiftly produce vaccines for future pandemics.
If mRNA technology were shared, manufacturers in LMICs could produce vaccines for pandemic preparedness and diseases of concern.
We need access to mRNA tech to prepare for the future.
SHARE ON FACEBOOK
Ask pharma to #ShareTheTech!
If mRNA technology were shared, manufacturers in LMICs could produce vaccines for pandemic preparedness and diseases of concern.
We need access to mRNA tech to prepare for the future.
SHARE ON FACEBOOK
Ask pharma to #ShareTheTech!
The COVID-19 pandemic's race to develop new vaccines has brought the introduction of revolutionary new technology: mRNA-based vaccines. Where available, mRNA-based COVID vaccines are one of the tools saving millions of lives and slowing transmission of the virus.
mRNA technology can also be used to develop vaccines against other diseases, which means with access to the technology, capable manufacturers in LMICs could produce vaccines to treat diseases of concern in their regions, as well as respond to future pandemics.
Even though governments contributed billions in public money to the research and development (R&D) of these mRNA COVID vaccines, so far Moderna, Pfizer and BioNTech have not shared their mRNA technology with manufacturers in LMICs. We urgently need these companies to share the mRNA technology and know-how, and support global, independent vaccine production and supply.
Establishing mRNA vaccine production among manufacturers in LMICs would create capacity for future pandemic preparedness. MSF analysis in collaboration with the AccessIBSA project identified more than 100 manufacturers across Asia, Africa and Latin America with the technical requirements and quality standards to manufacture mRNA vaccines.
Join us and urge Moderna, Pfizer and BioNTech to urgently share mRNA vaccine technology with capable manufacturers across the globe! #ShareTheTech #ShareToPrepare
'Share the Tech' - why pharma must share the mRNA vaccine technology
Social Media graphics
 "Share mRNA tech - Solidarity, global public good, sharing is caring")
 "Jérôme Tognotti, MSF nurse supervisor, holding a vial of COVID vaccine used by teams to vaccinate homeless and migrant people")
